NSAIDs in Morocco 2026: Storixia, Arcoxia, Apranax for joint pain

Osteoarthritis affects a significant share of Moroccans over the age of 60, and its burden continues to grow alongside demographic ageing, urban obesity and the sedentary lifestyles of the country's metropolitan centres. Faced with cracking knees, fingers stiffening at dawn or a hip that wakes the patient up at night, the most widespread reflex remains reaching for a non-steroidal anti-inflammatory drug — an NSAID.

In the 2026 Moroccan pharmacy landscape, several molecules dominate the field: naproxen (Apranax) and diclofenac (Voltarène) cover most first-line prescriptions, while selective COX-2 inhibitors, or coxibs, occupy a growing place. Among them, etoricoxib is available as the originator Arcoxia (MSD) and several Moroccan generics, including Storixia (Sothema). Understanding the differences between these molecules, their real indications, their cardiovascular, renal and gastrointestinal risks, and their cost to the Moroccan patient's pocket has become indispensable — particularly since the French National Authority for Health (HAS) reminded in April 2024 that a systemic NSAID is never the first reflex to have when facing osteoarthritis.

This article offers a clinical and practical overview of the NSAIDs available in Morocco, without misleading simplification. It is aimed at the patient aged 50 or over who has been prescribed a coxib, as well as at the one hesitating to ask for a tablet at the neighbourhood pharmacy.

01Osteoarthritis vs polyarthritis: two diseases, two treatment logics#

Confusion between osteoarthritis and inflammatory arthritis remains the most frequent mistake in clinical consultation. Osteoarthritis is a mechanical disease of the cartilage: progressive wear of the joint surface, pain that appears on effort and eases at rest, brief morning stiffness (less than 30 minutes). The knees (gonarthrosis), the hips (coxarthrosis), the fingers and the base of the thumb (rhizarthrosis) are the preferred sites. Symptomatic gonarthrosis is particularly common in older women, in connection with female overweight and the traditional carrying of loads.

Rheumatoid arthritis, psoriatic rheumatism and ankylosing spondylitis are, on the contrary, systemic autoimmune diseases. The pain wakes the patient up at night, morning stiffness lasts more than an hour, joints are warm and swollen, often symmetrically. These pathologies require disease-modifying treatments — methotrexate, biologics — and not a mere NSAID.

This distinction conditions everything that follows. When facing osteoarthritis, an NSAID is merely a short-term symptomatic palliative. When facing inflammatory arthritis, it accompanies the background treatment but never replaces it.

02Classic NSAIDs vs selective COX-2#

All NSAIDs block an enzyme, cyclooxygenase (COX), which transforms arachidonic acid into prostaglandins, the central mediators of inflammation, pain and fever. There are two main isoforms: COX-1, permanently present in the stomach, kidneys and platelets, and COX-2, induced by inflammation.

So-called classic or non-selective NSAIDs — ibuprofen, naproxen (Apranax), diclofenac (Voltarène), ketoprofen (Profénid) — block both isoforms. Diclofenac in particular is now considered the classic NSAID with the least favourable cardiovascular profile, comparable to that of coxibs according to the large meta-analysis of the *Coxib and traditional NSAID Trialists' Collaboration (Bhala et al., Lancet 2013)*.

Selective COX-2 inhibitors, or coxibs, were born in the 1990s with the ambition of retaining analgesic efficacy while sparing gastric COX-1. At the molecular level, COX-2 selectivity rests on a lateral hydrophobic pocket absent from COX-1: etoricoxib, celecoxib and valdecoxib bear a bulky sulfonamide or methylsulfonyl side chain that anchors into this pocket and blocks the inducible enzyme without touching the COX-1 constitutively expressed in the gastric mucosa and platelets. This platelet-sparing property explains why coxibs, unlike aspirin, do not prolong bleeding time and offer no cardioprotection — a critical point for the Moroccan coronary patient, who must keep a separate antiplatelet at preventive dose alongside their coxib.

Celecoxib and etoricoxib halve to a third the ulcer risk compared with diclofenac or naproxen, but this digestive sparing is paid for with enhanced cardiovascular vigilance. The EMA imposed strict contraindications as early as 2008 for etoricoxib in patients with poorly controlled hypertension, coronary disease or heart failure. From an international regulatory standpoint, etoricoxib deserves a special mention: the US FDA refused authorisation in 2007 after two successive passages before its advisory committee, considering the blood pressure profile insufficiently documented relative to diclofenac, in the very years when rofecoxib (Vioxx) had been withdrawn worldwide. By contrast, the EMA and the Moroccan medicines agency (DMP, Direction du Médicament et de la Pharmacie) maintained the marketing authorisation across Europe and Morocco while tightly framing the prescription: mandatory cardiovascular history, blood pressure measurement before treatment and at two weeks, and systematic reassessment at one month. The Moroccan patient who travels between Casablanca, Paris and New York must therefore know that a pack of Arcoxia or Storixia will have no equivalent on American soil — unlike Celebrex (celecoxib), which remains marketed in the United States.

03Coxibs available in Morocco: celecoxib vs etoricoxib#

Two oral coxibs are commercialised in Moroccan pharmacies: celecoxib (originator Celebrex from Pfizer and its generics) and etoricoxib.

Celecoxib is taken in two daily doses, has a shorter half-life (~11 hours), and showed in the *PRECISION trial (Nissen et al., NEJM 2016) cardiovascular non-inferiority against naproxen and ibuprofen at moderate doses. PRECISION randomised 24,081 patients with osteoarthritis or rheumatoid arthritis and elevated cardiovascular risk, followed for three years: the composite endpoint (cardiovascular death, infarction, stroke) occurred in 2.3% of the celecoxib arm versus 2.5% on naproxen and 2.7% on ibuprofen, with no statistically significant difference. The trial also showed lower renal toxicity* under celecoxib than under high-dose ibuprofen, a point that weighs in its favour for the Moroccan hypertensive or diabetic patient.

Etoricoxib, originator Arcoxia (MSD), is one of the most prescribed coxibs in Morocco thanks to its once-daily dosing (half-life around 22 hours). Storixia (Sothema), among the most visible in pharmacies, is the textbook example of an etoricoxib generic at all three strengths 60, 90 and 120 mg.

Etoricoxib covers four main indications: symptomatic osteoarthritis in adults, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. The *MEDAL trial (Cannon et al., Lancet 2006), the pivotal study pooling 34,701 osteoarthritis and rheumatoid arthritis patients followed on average 18 months, established efficacy equivalence with diclofenac at 150 mg/day but with an increased frequency of lower limb oedema (+1.8% vs diclofenac), clinically significant blood pressure elevations (+1 to 4 mmHg mean systolic) and treatment discontinuations for hypertension*. The rate of major adverse cardiovascular events (MACE) was comparable between arms, but this equivalence came at the price of a heavier blood pressure load — a signal the Moroccan rheumatologist must factor in when treating patients over 60 who are often already on an ACE inhibitor or ARB.

04When to choose 60, 90 or 120 mg: the clinical logic#

For osteoarthritis, the recommended dose is 30 mg once daily, which may be raised to 60 mg in case of insufficient relief. In Morocco, since the 30 mg strength is poorly available, prescription frequently starts at 60 mg. For rheumatoid arthritis, the dose validated by the summary of product characteristics is 60 mg/day, and not 90 mg as is sometimes read: the 90 mg/day dose is reserved for ankylosing spondylitis and psoriatic rheumatism. Acute gouty arthritis is treated at 120 mg/day for a maximum of 8 days, a duration never to be exceeded.

The golden rule: lowest effective dose, shortest possible duration. In osteoarthritis, the NSAID should cover only a painful flare — generally a few days to two weeks — then be stopped. For patients over 75, HAS recommends paracetamol as first-line therapy, with a maximum dose reduced to 3 g/day in subjects over 75, under 50 kg, or with hepatic or renal impairment.

The dose-by-dose detail appears on the product sheets: Storixia 60 mg, Storixia 90 mg, Storixia 120 mg.

05Cardiovascular risk#

NSAID cardiovascular risk, particularly for coxibs and high-dose diclofenac, is now consensus. ANSM regularly recalls that any NSAID, classic or selective, can increase the risk of myocardial infarction, ischaemic stroke and decompensated heart failure.

In Morocco, the STEPS 2017-2018 national survey estimated arterial hypertension prevalence at around 29% in adults, and diabetes at around 10-11%. On these terrains, prescribing a coxib warrants systematic cardiovascular questioning. Absolute contraindications include congestive heart failure (NYHA II to IV), proven ischaemic heart disease, peripheral artery disease, history of stroke or transient ischaemic attack, and uncontrolled hypertension.

06Renal, hepatic and gastric injury#

COX-1 inhibition by classic NSAIDs explains most of the digestive toxicity: dyspepsia in 10 to 20%, gastroduodenal ulcer in 1 to 4%, upper digestive bleeding in 0.5 to 1.5%.

Renal injury: the famous triple whammy — ACE inhibitor + diuretic + NSAID — is one of the leading causes of iatrogenic acute kidney injury seen in Moroccan emergency departments. The mechanism is precise: vasodilatory intra-renal prostaglandins maintain glomerular perfusion in the elderly, hypertensive or dehydrated patient; their abrupt blockade by an NSAID triggers a fall in filtration rate within hours, hidden behind a creatinine that stays normal for the first few days. Etoricoxib is contraindicated in patients with creatinine clearance below 30 mL/min (chronic kidney disease stages 4 and 5, per the Cockcroft-Gault formula). In CKD stage 3 (eGFR 30–59 mL/min/1.73 m²), the prescription remains possible but at the lowest dose (60 mg/day maximum), for the shortest duration possible, with creatinine and potassium monitoring at 7 days. In stage 5 or in chronic haemodialysis patients, all NSAIDs are contraindicated: the loss of residual nephron capital precipitates entry into definitive dialysis, a major complication in the Moroccan context where haemodialysis access remains heterogeneous between Casablanca-Rabat and the southern provinces.

On the hepatic side, etoricoxib is contraindicated in severe hepatic impairment (Child-Pugh score ≥ 10). In mild to moderate hepatic impairment (Child-Pugh 5 to 9), strict adjustment is mandatory: the dose must not exceed 60 mg/day.

07Pregnancy and breastfeeding#

The ANSM has reaffirmed a strong alert on NSAIDs during pregnancy, aligned with the EMA and the FDA. All NSAIDs, including coxibs such as etoricoxib, are absolutely and formally contraindicated from 24 weeks of amenorrhoea (start of the 6th month) until delivery — no exception. The mechanism is well established: NSAIDs cross the placental barrier and trigger premature closure of the fetal ductus arteriosus, fetal renal toxicity with severe oligohydramnios and neonatal renal failure, and inhibition of platelet aggregation that may complicate delivery. Several ANSM publications from 2017 and 2019 have reported Moroccan and European cases of terminal neonatal renal failure after only a few days of NSAID exposure in the third trimester, including self-medication with ibuprofen or topical diclofenac applied to large body surfaces.

During the 1st and 2nd trimesters, NSAIDs are also discouraged: first-trimester intake is suspected of increasing the risk of miscarriage and cardiac malformations, even if the data remain debated. Paracetamol remains the reference analgesic throughout pregnancy, at the minimum effective dose and for the shortest possible duration. For refractory joint pain in the second trimester in a Moroccan patient, recourse to physiotherapy, orthoses and ultrasound-guided corticosteroid infiltration remains preferable to any prescription of systemic NSAID.

During breastfeeding, etoricoxib is discouraged. Compatible alternatives are occasional ibuprofen and, with caveats, celecoxib.

08Major drug interactions#

In patients on vitamin K antagonists (warfarin, acenocoumarol), etoricoxib potentiates the anticoagulant effect and raises the INR; an INR check at 3–5 days after NSAID introduction is mandatory, and discontinuing an acutely prescribed NSAID must also trigger a follow-up INR.

The stakes have become even sharper with the diffusion of direct oral anticoagulants (DOACs) across Morocco: apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa) and edoxaban are now widely prescribed in non-valvular atrial fibrillation and venous thromboembolic disease. The NSAID + DOAC association does not prolong INR — there is nothing to measure — but multiplies the risk of digestive and intracranial bleeding by two to threefold, per analyses of the ARISTOTLE, ROCKET-AF and RE-LY registries. In Morocco, where the elderly patient on Xarelto frequently consults for low back pain or a gout flare, the NSAID should be avoided whenever possible and replaced by paracetamol or, in acute settings, by a local infiltration. If an NSAID prescription is unavoidable, one favours the shortest duration (3 to 5 days), the lowest dose, the systematic addition of a proton pump inhibitor (omeprazole 20 mg or pantoprazole 40 mg), and a haemoglobin check at one week.

With lithium, NSAIDs including coxibs reduce renal clearance of lithium and raise the risk of neurotoxicity with tremor, confusion and tubulopathy. With high-dose methotrexate (≥ 15 mg/week, in oncology), the combination is discouraged; at weekly rheumatology doses (7.5 to 15 mg), it remains possible under monthly haematology and serum creatinine monitoring. With selective serotonin reuptake inhibitors (SSRIs) — common in patients with fibromyalgia overlapping osteoarthritis — NSAIDs raise the risk of upper gastrointestinal bleeding by around 50%. With ACE inhibitors, ARBs and diuretics: reduced antihypertensive effect and acute renal failure risk.

09Overdose and what to do#

There is no specific antidote to etoricoxib. Haemodialysis is ineffective because etoricoxib is more than 92% bound to plasma proteins. The Moroccan Anti-Poison and Pharmacovigilance Centre (CAPM) is available 24/7 at 0801 000 180.

10Prices and AMO reimbursement#

Indicatively for 2026, Storixia 90 mg in a box of 14 tablets circulates in pharmacies around 150 dirhams (to be confirmed against the BNDM/DMP database), or roughly 11 dirhams per day of treatment. Voltarène 50 mg (diclofenac) in a box of 30 remains under 35 dirhams, and Apranax 550 mg in a box of 30 hovers around 85 to 90 dirhams.

Etoricoxib listing on the reimbursable medicines list must be verified with ANAM. The conventional AMO reimbursement rate is typically 70% of the national reference tariff (TNR), but actual reimbursement of etoricoxib remains conditional on the indication. For simple knee osteoarthritis, AMO does not systematically cover the coxib if a less expensive classic NSAID (Voltarène, Apranax) is available; the patient then bears the full pharmacy price.

By contrast, for long-term inflammatory conditions (ALD) recognised by ANAM — rheumatoid arthritis, ankylosing spondylitis, psoriatic rheumatism — Storixia 90 mg as well as Arcoxia 90 mg may benefit from 100% coverage within the ALD protocol, upon submission of the ALD form signed by the treating rheumatologist and validated by the medical adviser of CNOPS or CNSS. The private-sector salaried patient (CNSS) deposits the file at the local agency; the public-sector employee (CNOPS) goes through the mutualist attached to their ministry. This distinction explains why a rheumatoid arthritis patient effectively pays 0 dirhams per month while a patient with simple osteoarthritis spends 300 to 600 dirhams depending on flare frequency and dose.

11Non-pharmacological alternatives#

Joint recommendations from HAS, EULAR and OARSI converge on a foundation of non-pharmacological measures. Weight loss of at least 5% of body weight in overweight patients reduces pain by 20 to 30% and improves joint function in proportions comparable to a properly dosed NSAID. Adapted physical exercise — walking, stationary cycling, balneotherapy in a heated pool — strengthens peri-articular musculature and preserves mobility.

Physiotherapy, accessible in Morocco with 70% AMO reimbursement on prescription, should precede or accompany any NSAID prescription in osteoarthritis. The SMR (Soins Médicaux de Rééducation) physiotherapy assessment prescribed by the GP opens entitlement to series of 10 to 30 renewable sessions, with procedures coded on the ANAM nomenclature. For gonarthrosis, the standard protocol combines isometric quadriceps strengthening, hamstring stretching, proprioception on a Freeman board and analgesic electrotherapy (TENS). For coxarthrosis and rhizarthrosis, specific manual techniques (passive mobilisation, gentle manipulation) complement active exercise.

When pain remains disabling despite optimal medical therapy, ultrasound-guided intra-articular corticosteroid infiltration offers relief lasting several weeks to several months. Performed by a rheumatologist, an interventional radiologist or a sports physician, it should not exceed two to three injections per year per joint to preserve residual cartilage. In Morocco, the procedure is priced on average between 400 and 800 dirhams in private practice, partially reimbursed by AMO. Hyaluronic acid (viscosupplementation, Synvisc, Hyalgan, Ostenil) remains an option for moderate gonarthrosis, at a higher cost (1,500 to 3,000 dirhams per full course), with variable efficacy according to the Kellgren-Lawrence radiographic stage.

Topical NSAIDs — Voltarène Emulgel, ketoprofen gel — offer real efficacy on small superficial joints with very limited systemic exposure.

12When to consult a doctor or a rheumatologist#

Any joint pain lasting more than six weeks, waking the patient at night, accompanied by warm swelling, fever or general deterioration, should prompt a rapid medical consultation. Prolonged NSAID self-prescription, common in Morocco, is a poor habit. Beyond 5 to 7 days of continuous treatment without medical advice, the benefit/risk ratio reverses rapidly.

13Summary: the right 2026 reflexes#

Key takeaways — For osteoarthritis: paracetamol first (up to 4 g/day in the healthy adult, 3 g/day if > 75, < 50 kg, hepatic or renal impairment), topical NSAID on small joints, oral NSAID only in short flares. For RA: etoricoxib at 60 mg/d (not 90). For ankylosing spondylitis and psoriatic arthritis: 90 mg/d. For acute gout: 120 mg/d for 8 days maximum. Moroccan Anti-Poison Centre (CAPM) emergency number: 0801 000 180.

Book an appointment with a rheumatologist through the Sahha directory to review your current treatment.